Avomeen has appointed Hashim Ahmed, Ph.D. as its new Head of Formulation and Manufacturing. Ahmed will work to strengthen and expand Avomeen’s formulation and manufacturing segment by partnering with biopharmaceutical clients who are navigating the small- and large-molecule product development life cycle.

Hashim Ahmed, Ph.D. of Avomeen

Ahmed brings more than 25 years of experience from the biopharmaceutical and CDMO industries. Most recently, he held a Managing Director position at QLife Pharma. Prior to this, he has held leadership positions at Dr. Reddy’s Laboratories, GSK-Stiefel, and Hoffmann-La Roche Inc. Ahmed has also served as a consultant for various biopharmaceutical companies on effective risk assessment (RA) control strategy, specification, and chemistry, manufacturing and control (CMC) modules, including CMC-Quality for various dosage forms development; investigational new drug, abbreviated new drug application, new drug application, 505b2, RA, and quality by design (QbD) filings; and both conventional and QbD-based tech-transfer across global sites.

“Hashim brings a wealth of knowledge and expertise in manufacturing science and technology, product development, and CMC,” said Mark Harvill, Avomeen Chief Executive Officer. “His blend of leadership, experience in biopharma companies and CDMOs and small-molecule and large-molecule expertise will help us fortify and expand this business segment to include more services.”